Maja Prodanović
YOU?
Author Swipe
View article: Late presentation of traumatic tricuspid valve chordal rupture and pericardial rupture with cardiac herniation; a case report
Late presentation of traumatic tricuspid valve chordal rupture and pericardial rupture with cardiac herniation; a case report Open
Background Although chest trauma happens very often, accompanying tricuspid valve injuries occur rarely and may be manifested by scarce symptoms and signs. Pericardial rupture with cardiac herniation is even bigger rarity. Transthoracic ec…
View article: Adding clinical markers of more severe form of intermediate-high risk pulmonary embolism improves risk stratification and possibly identifies candidates for fibrinolytic therapy
Adding clinical markers of more severe form of intermediate-high risk pulmonary embolism improves risk stratification and possibly identifies candidates for fibrinolytic therapy Open
Funding Acknowledgements Type of funding sources: None. Background The authors of PEITHO study recently proposed 3 changes for future trials, in order to identify a higher-risk population among patients with intermediate-high risk PE, as p…
View article: Gestational Diabetes and Risk Assessment of Adverse Perinatal Outcomes and Newborns Early Motoric Development
Gestational Diabetes and Risk Assessment of Adverse Perinatal Outcomes and Newborns Early Motoric Development Open
Background and Objectives: The aim of this study was to analyze the presence of gestational diabetes mellitus (GDM) on maternal and fetal perinatal parameters, as well to evaluate the influence of GDM on neonatal early motoric development.…
View article: The effect of fibrinolytic therapy on 30-day outcome in patients with intermediate risk pulmonary embolism - propensity score-adjusted analysis
The effect of fibrinolytic therapy on 30-day outcome in patients with intermediate risk pulmonary embolism - propensity score-adjusted analysis Open
Introduction/Objective. Patients with submassive (intermediate risk) pulmonary embolism (PE) represent a very heterogeneous group, whose therapeutic strategy still questions whether some groups of patients would have net clinical benefit f…